118 related articles for article (PubMed ID: 38518393)
1. Combined genetic polymorphisms of the GSTT1 and NRF2 genes increase susceptibility to cisplatin-induced ototoxicity: A preliminary study.
Fujikawa T; Ito T; Okada R; Sawada M; Mohri K; Tateishi Y; Takahashi R; Asakage T; Tsutsumi T
Hear Res; 2024 Apr; 445():108995. PubMed ID: 38518393
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
3. GSTM1 null and GSTT1 null: predictors of cisplatin-caused acute ototoxicity measured by DPOAEs.
Budai B; Prekopp P; Noszek L; Kovács ER; Szőnyi M; Erdélyi DJ; Bíró K; Géczi L
J Mol Med (Berl); 2020 Jul; 98(7):963-971. PubMed ID: 32435918
[TBL] [Abstract][Full Text] [Related]
4. Distortion-product otoacoustic emission test performance for ototoxicity monitoring.
Reavis KM; McMillan G; Austin D; Gallun F; Fausti SA; Gordon JS; Helt WJ; Konrad-Martin D
Ear Hear; 2011 Feb; 32(1):61-74. PubMed ID: 20625302
[TBL] [Abstract][Full Text] [Related]
5. Effect of cisplatin on distortion product otoacoustic emissions in Japanese patients.
Eiamprapai P; Yamamoto N; Hiraumi H; Ogino-Nishimura E; Kitamura M; Hirano S; Ito J
Laryngoscope; 2012 Jun; 122(6):1392-6. PubMed ID: 22555987
[TBL] [Abstract][Full Text] [Related]
6. [Genetic background of cisplatin induced ototoxicity].
Jurajda M; Talach T; Kostřica R; Lakomý R; Kocák I; Cvanová M
Klin Onkol; 2012; 25(3):184-7. PubMed ID: 22724567
[TBL] [Abstract][Full Text] [Related]
7. [Otoacoustic emissions measurements in children during the chemotherapy because of the acute lymphoblastic leukemia].
Lisowska G; Namysłowski G; Hajduk A; Polok A; Tomaszewska R; Misiołek M
Otolaryngol Pol; 2006; 60(3):415-20. PubMed ID: 16989457
[TBL] [Abstract][Full Text] [Related]
8. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
9. Promoter region variation in NFE2L2 influences susceptibility to ototoxicity in patients exposed to high cumulative doses of cisplatin.
Spracklen TF; Vorster AA; Ramma L; Dalvie S; Ramesar RS
Pharmacogenomics J; 2017 Dec; 17(6):515-520. PubMed ID: 27457817
[TBL] [Abstract][Full Text] [Related]
10. Gstm1/Gstt1 is essential for reducing cisplatin ototoxicity in CBA/CaJ mice.
Li P; Liu Z; Wang J; Bi X; Xiao Y; Qiao R; Zhou X; Guo S; Wan P; Chang M; Hong G; Liu Z; Ming X; Gao J; Fu X
FASEB J; 2022 Jun; 36(6):e22373. PubMed ID: 35621716
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic etanercept treatment in cisplatin ototoxicity.
Dasli S; Topdag M; Mutlu A; Kara A; Ozturk M
Eur Arch Otorhinolaryngol; 2017 Oct; 274(10):3577-3583. PubMed ID: 28730299
[TBL] [Abstract][Full Text] [Related]
12. ABR obtained from time-efficient train stimuli for cisplatin ototoxicity monitoring.
Dille MF; Ellingson RM; McMillan GP; Konrad-Martin D
J Am Acad Audiol; 2013 Oct; 24(9):769-81. PubMed ID: 24224985
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission.
Biro K; Noszek L; Prekopp P; Nagyiványi K; Géczi L; Gaudi I; Bodrogi I
Oncology; 2006; 70(3):177-84. PubMed ID: 16757924
[TBL] [Abstract][Full Text] [Related]
14. Distortion-product otoacoustic emissions and auditory brainstem responses sensitivity assessment in cisplatin-induced ototoxicity in rats.
Freitas MR; Silva VC; Brito GA; Carvalho Junior JV; Gomes Junior RM; Ribeiro Rde A
Braz J Otorhinolaryngol; 2009; 75(4):476-84. PubMed ID: 19784413
[TBL] [Abstract][Full Text] [Related]
15. Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model.
Dille MF; McMillan GP; Reavis KM; Jacobs P; Fausti SA; Konrad-Martin D
J Acoust Soc Am; 2010 Sep; 128(3):1163-74. PubMed ID: 20815453
[TBL] [Abstract][Full Text] [Related]
16. Effect of cisplatin chemotherapy on the inner ear function and serum prestin concentration.
Jalali MM; Saedi HS; Saadat F
Eur Arch Otorhinolaryngol; 2022 Jun; 279(6):2783-2789. PubMed ID: 34213608
[TBL] [Abstract][Full Text] [Related]
17. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
Biró K
Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
[TBL] [Abstract][Full Text] [Related]
18. Occupational Lead Exposure Ototoxicity Evaluated With Distortion-Product Otoacoustic Emissions.
Solis-Angeles S; Del Razo LM; Aguilar-Madrid G; Jiménez-Ramírez C; Coco L; Cabello-López A; Juárez-Pérez CA
Ear Hear; 2024 Mar-Apr 01; 45(2):329-336. PubMed ID: 37700446
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the potential ability of RG108 in cisplatin-induced HEI-OC1 ototoxicity: a research based on RNA-seq and molecular biology experiment.
Zhang D; Sun Y; Lei M; Wang Y; Cai C
Hereditas; 2023 Apr; 160(1):18. PubMed ID: 37088824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
